Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
16.80
Dollar change
-0.05
Percentage change
-0.30
%
Index- P/E29.23 EPS (ttm)0.57 Insider Own2.30% Shs Outstand174.25M Perf Week-2.72%
Market Cap2.93B Forward P/E196.81 EPS next Y0.09 Insider Trans0.00% Shs Float170.25M Perf Month10.45%
Income99.32M PEG- EPS next Q- Inst Own7.15% Short Float0.28% Perf Quarter-4.05%
Sales844.58M P/S3.47 EPS this Y-200.13% Inst Trans-18.54% Short Ratio4.00 Perf Half Y0.66%
Book/sh4.19 P/B4.01 EPS next Y114.21% ROA8.60% Short Interest0.49M Perf Year23.17%
Cash/sh5.09 P/C3.30 EPS next 5Y- ROE14.81% 52W Range10.68 - 20.73 Perf YTD-7.23%
Dividend Est.- P/FCF15.35 EPS past 5Y- ROI12.71% 52W High-18.96% Beta0.81
Dividend TTM- Quick Ratio2.60 Sales past 5Y35.89% Gross Margin54.03% 52W Low57.30% ATR (14)0.90
Dividend Ex-Date- Current Ratio2.72 EPS Y/Y TTM127.85% Oper. Margin1.94% RSI (14)55.18 Volatility3.68% 4.43%
Employees1988 Debt/Eq0.12 Sales Y/Y TTM94.29% Profit Margin11.76% Recom1.31 Target Price26.16
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-79.15% Payout0.00% Rel Volume0.51 Prev Close16.85
Sales Surprise-4.21% EPS Surprise27.27% Sales Q/Q53.61% EarningsFeb 28 AMC Avg Volume121.37K Price16.80
SMA203.94% SMA5013.04% SMA2007.63% Trades Volume61,445 Change-0.30%
Date Action Analyst Rating Change Price Target Change
Nov-24-23Upgrade Deutsche Bank Hold → Buy
May-04-22Downgrade Deutsche Bank Buy → Hold
Sep-22-21Downgrade Goldman Buy → Neutral $46
Aug-03-21Initiated Jefferies Buy $52
Oct-02-20Initiated Deutsche Bank Buy $40
Mar-13-20Initiated Cantor Fitzgerald Overweight
Feb-20-20Initiated Goldman Buy
Nov-19-19Initiated CLSA Buy
Oct-23-19Reiterated BofA/Merrill Buy $35 → $29
Jul-05-19Initiated Macquarie Outperform
Mar-27-24 08:00PM
08:00PM
Mar-21-24 08:00PM
Feb-28-24 06:30AM
Feb-06-24 07:00PM
03:30AM Loading…
Feb-02-24 03:30AM
Feb-01-24 03:30AM
Jan-29-24 11:53PM
Jan-10-24 07:00PM
Dec-12-23 11:30PM
07:00PM
Nov-30-23 07:00PM
Nov-10-23 08:35AM
Nov-08-23 07:11PM
Nov-01-23 08:35AM
08:35PM Loading…
Oct-31-23 08:35PM
Oct-16-23 04:30AM
Oct-10-23 12:08PM
Oct-05-23 05:17PM
Sep-29-23 04:30AM
Sep-25-23 12:20PM
Sep-18-23 12:14PM
Sep-12-23 04:30AM
Sep-11-23 08:00PM
12:14PM
Aug-28-23 08:00PM
Aug-20-23 08:00PM
Aug-03-23 01:07AM
Jul-31-23 07:41AM
Jul-19-23 08:00PM
04:30AM Loading…
Jul-13-23 04:30AM
Jul-09-23 08:00PM
Jun-26-23 04:30AM
Jun-15-23 08:30PM
10:30AM
Jun-09-23 05:30AM
May-25-23 07:00PM
06:00PM
May-18-23 08:35AM
May-15-23 08:15AM
May-12-23 04:30AM
May-11-23 05:00AM
May-10-23 04:30AM
May-09-23 01:36PM
Apr-17-23 08:00PM
Apr-11-23 08:00PM
04:30AM
Apr-04-23 05:30AM
Mar-30-23 08:00PM
Mar-14-23 09:30AM
Mar-12-23 08:07PM
Feb-28-23 03:30AM
Feb-27-23 05:00AM
Jan-31-23 03:30AM
Jan-23-23 08:00AM
03:00AM
Jan-18-23 09:30AM
Jan-03-23 03:30AM
Dec-19-22 05:00AM
Dec-16-22 06:27AM
Nov-18-22 08:35AM
Nov-14-22 07:00PM
07:40AM
Nov-13-22 07:00PM
Nov-09-22 06:30PM
Oct-27-22 07:30AM
Oct-10-22 04:30AM
Sep-08-22 01:33PM
Sep-07-22 06:30PM
Aug-23-22 04:30AM
Aug-09-22 04:30AM
Aug-08-22 06:02AM
Aug-07-22 08:00PM
Aug-01-22 07:00AM
02:00AM
Jul-15-22 04:30AM
Jul-14-22 12:00PM
Jul-13-22 12:28PM
Jul-12-22 08:00PM
Jul-06-22 12:40AM
Jun-27-22 04:30AM
Jun-01-22 04:33AM
May-16-22 07:00AM
May-15-22 07:00PM
May-12-22 09:54AM
May-08-22 08:30PM
May-05-22 08:58AM
May-02-22 06:00AM
Mar-31-22 12:00AM
Mar-11-22 04:00AM
Mar-06-22 11:30PM
Mar-03-22 07:30AM
07:00AM
Mar-01-22 03:30AM
Feb-10-22 03:06AM
Feb-07-22 03:30AM
Feb-04-22 04:30AM
Jan-19-22 07:00PM
Jan-18-22 07:00PM
Jan-12-22 06:00AM
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.